UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000021349
Receipt number R000024619
Scientific Title Feasibility of Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a pilot study.
Date of disclosure of the study information 2016/03/07
Last modified on 2017/03/12 16:31:10

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Feasibility of Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a pilot study.

Acronym

Feasibility of Ruxolitinib in steroid-refractory GVHD

Scientific Title

Feasibility of Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a pilot study.

Scientific Title:Acronym

Feasibility of Ruxolitinib in steroid-refractory GVHD

Region

Japan


Condition

Condition

corticosteroid-refractory graft-versus-host disease

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

efficacy of Ruxolitinib therapy for steroid-refractory GVHD

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

response rete of GVHD
adverse effect

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

ruxolitinib 5mg, twice a day

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

70 years-old >

Gender

Male and Female

Key inclusion criteria

steroid refractory GVHD
age; 20-70 years

Key exclusion criteria

1) with active infection
2) w/o informed consent
3) CCr<10 ml/min

Target sample size

2


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hideo Harigae

Organization

Tohoku University Hospital

Division name

Hematology-Rhumatology

Zip code


Address

1-1 Seiryo-machi, Sendai

TEL

022-717-7165

Email

harigae@med.tohoku.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Yasushi Onishi

Organization

Tohoku University Hospital

Division name

Hematology-Rhumatology

Zip code


Address

1-1 Seiryo-machi, Sendai

TEL

022-717-7165

Homepage URL


Email

yonishi@med.tohoku.ac.jp


Sponsor or person

Institute

Tohoku University Hospital

Institute

Department

Personal name



Funding Source

Organization

Tohoku University Hospital

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 03 Month 07 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2016 Year 02 Month 22 Day

Date of IRB


Anticipated trial start date

2016 Year 03 Month 07 Day

Last follow-up date

2016 Year 08 Month 06 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2016 Year 03 Month 04 Day

Last modified on

2017 Year 03 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024619


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name